With long development timelines and high burn rates, biotech companies must navigate capital markets with precision.

Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

In the headquarters of a mid-sized pharmaceutical company preparing for its first product launch, a scene once considered ...

The controlled cell line combined with Recipharm’s AAV manufacturing platform is said to allow for consistent and scalable ...

As a descendant of an Indigenous Amazonian tribe, Maria Astolfi was concerned about research she conducted as a graduate ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling through a prolonged downturn, increasing concerns they will have a harder time ...